**Author details**

Jessica Iorio, Claudia Duranti and Elena Lastraioli\* Department of Experimental and Clinical Medicine, Florence, Italy

\*Address all correspondence to: elena.lastraioli@unifi.it

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**53**

*Ion Channels and Transporters as Cancer Biomarkers and Targets for Diagnostics with Antibodies*

inhibits cancer growth in mice. Molecules. 2012;**17**:796-808. DOI: 10.3390/molecules17010796

Way JD. Synthesis and pre-clinical evaluation of an (18)F-labeled singlechain antibody fragment for PET imaging of epithelial ovarian cancer. American Journal of Nuclear Medicine and Molecular Imaging. 2016;**6**:185-198

[10] Han D, Wu J, Han Y. A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Oncotarget. 2016;**7**:59471-59481.

Germain-Genevois C. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe. Scientific Reports. 2016;**6**:23314. DOI: 10.1038/

[12] Duranti C, Arcangeli A. Ion channel targeting with antibodies and antibody

Antibodies. 2019;**8**(2):33. DOI: 10.3390/

[13] Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature Biotechnology. 2005;**23**:1126-1136. DOI: 10.1038/

[14] Oeggerli M, Tian Y, Ruiz C. Role of KCNMA1 in breast cancer. PLoS One. 2012;**7**(8):e41664. DOI: 10.1371/journal.

[15] Brevet M, Ahidouch A, Sevestre H. Expression of K+ channels in normal and cancerous human breast. Histology and Histopathology. 2008;**23**(8):965- 972. DOI: 10.14670/HH-23.965.

[16] Khaitan D, Sankpal UT,

Weksler B. Role of KCNMA1 gene in breast cancer invasion and metastasis

fragments for cancer diagnosis.

DOI: 10.18632/oncotarget.10697

[11] Mazzocco C, Fracasso G,

srep23314

antib8020033

nbt1142

pone.0041664

[9] Sharma SK, Wuest M,

*DOI: http://dx.doi.org/10.5772/intechopen.90401*

[1] Arcangeli A, Crociani O, Bencini L. Interaction of tumour cells with their microenvironment: Ion channels and cell adhesion molecules. A focus on pancreatic cancer. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 2014;**369**(1638):20130101. DOI:

[2] Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. Biochimica et Biophysica Acta. 2015;**1848**(10 Pt B):2685-2702. DOI: 10.1016/j.bbamem.2014.12.016

[3] Pedersen SF, Novak I, Alves F. Alternating pH landscapes shape epithelial cancer initiation and

BioEssays. 2017;**39**(6):1-10. DOI:

Lastraioli E. Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Current

Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews. Drug Discovery. 2009;**8**(12):982-1001. DOI: 10.1038/

[6] Prevarskaya N, Skryma R, Shuba Y. Ion channels in cancer: Are cancer hallmarks oncochannelopathies? Physiological Reviews. 2018;**98**(2):559- 621. DOI: 10.1152/physrev.00044.2016

[7] Kaur S, Venktaraman G,

canlet.2011.10.017

Jain M. Recent trends in antibody-based oncologic imaging. Cancer Letters. 2012;**315**:97-111. DOI: 10.1016/j.

[8] Xu W, Liu L, Brown NJ. Quantum dot-conjugated anti-GRP78 scFv

Medicinal Chemistry. 2009;**16**(1):66-93. DOI: 10.2174/092986709787002835

10.1002/bies.201600253

[5] Wulff H, Castle NA,

nrd2983

[4] Arcangeli A, Crociani O,

progression: Focus on pancreatic cancer.

10.1098/rstb.2013.0101

**References**

*Ion Channels and Transporters as Cancer Biomarkers and Targets for Diagnostics with Antibodies DOI: http://dx.doi.org/10.5772/intechopen.90401*
